‘Axelyf Closes Seed Financing to Advance Next-Generation RNA-LNP Therapeutics’

August 19, 2025

Axelyf Inc. today announced the closing of $2.6 million in seed funding, with the potential to reach a total of $4.1 million this fall. The round was led by Brunnur Ventures GP, of Iceland, and included participation from Omega ehf and Silfurberg ehf, both Icelandic venture capital firms with extensive biotech and medical technology portfolios.

The funds will support the development of Axelyf’s proprietary AXL technology, which demonstrated superior in vivo gene editing potency compared to the LP-01 benchmark currently being used in Phase 3 trials. In partner studies, AXL lipids achieved higher mouse gene editing efficiency at lower doses, without signs of liver toxicity, as well as high potency for gene insertion with reduced immune stimulation, demonstrating flexibility to address multiple gene therapy models.

The full press release was published by EIN Presswire.